

Global Influenza Market – Vaccines and Therapeutics

The report reviews, analyzes and projects the global market for Influenza Vaccines and Therapeutics for the period 2012-2022

Published: Mar 2016

Report Code: PH015

Pages: 128

Charts: 30

Price: \$3600 Single User License, \$5400 Enterprise License

SUMMARY

The influenza virus has been implicated in infecting millions of individuals on an annual basis, with vaccination programs against seasonal influenza infections necessitating the manufacture of hundreds of million doses within a very short time period. The emergence of innovative production systems based on mammalian or insect cell cultures have resulted in surmount the hurdles associated with the egg-based production system. These industrially well-established production systems provide a faster and more flexible response to pandemic threats.


The existing range of influenza vaccines are produced in fertilized eggs, the embryo of which is infected in order that the virus can proliferate. Following a period of incubation, the virus is harvested and purified. This system of production is complicated and lacking in the event of a pandemic due to the possibility of generating low yields, not being amenable to rapid scale-up and being dependent on the availability of eggs. Global authorities have acknowledged problems associated with manufacturing vaccines based on eggs, resulting in creating a need for developing alternative vaccine production systems. The current scenario has been focusing on the development of manufacturing systems based on plants, bacteria, yeast and cell cultures.

Worldwide market for Influenza Vaccines is analyzed in both volumes in doses and value in USD for the period from 2012 through to 2022. The market for influenza therapeutics is analyzed in terms of value only at a global level. The global market for overall influenza is estimated to be US\$6.1 billion in 2016 and anticipated to reach US\$10.2 billion by 2022, witnessing a robust 8.5% CAGR between 2016 and 2022. Vaccines account for about 80% of the influenza market while therapeutics account for the remaining. However, therapeutics segment is projected to be the fastest growing with a CAGR of 11% during the aforementioned analysis period.

The report reviews, analyses and projects the Influenza therapeutics market at the global level while vaccines market is explored in and the regional markets including North America, Europe, Asia-Pacific, South & Central America and Middle East & Africa.

This 128 page market research report includes 30 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of market numbers. This report profiles 16 key global players and 39 major players across North America – 8; Europe – 10; Asia-Pacific – 20 and South & Central America – 1. The research also provides the listing of the companies engaged in research and development, manufacturing and supply of influenza vaccines and therapeutic. The global list of companies covers addresses, contact numbers and the website addresses of 80 companies.

Global Influenza Vaccines Market Overview (2012-2022)
in Value (USD Million)



SAMPLE COMPANY PROFILE

ASTRAZENECA PLC (UNITED KINGDOM)

2 Kingdom Street, London, W2 6BD
The United Kingdom
Phone: 44-20-7604-8000
Fax: 44 20 7604 8151
Website: www.astrazeneca.com

Key Financial Data:

Astrazeneca Seasonal Influenza Vaccine Sales Distribution by Region (USD Million)

	US	Europe	Emerging Markets	Established Rest of World	Total
2012	174.00	3.00	1.00	3.00	181.00
2013	199.00	42.00	1.00	4.00	246.00
2014	218.00	70.00	1.00	7.00	296.00

*Emerging Markets: China, Russia, Brazil, Argentina, Mexico, South Korea, Taiwan, Turkey, India, Middle East and Africa

** Established Rest of World: Canada, Australia and Japan

Business Overview:

London based AstraZeneca Plc is a multinational pharmaceutical and biologics company, formed as a merger of Sweden-based Astra AB and UK-based Zeneca Group in 1999. AstraZeneca Plc engages in providing a broad range product portfolio for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation.

The company's Research and Development centre is located in Sweden.

Product Portfolio:

- AstraZeneca Plc offers Fluenz Tetra in Europe to prevent Seasonal Influenza disease.
- Fluenz Tetra is an intranasal influenza vaccine that contains four live attenuated influenza virus strains (two A strains and two B strains).
- Fluenz Tetra is indicated for prophylaxis of Seasonal Influenza in children and adolescents from 24 months to less than 18 years of age.


.....more

SAMPLE TABLE/CHART

Glance at 2017 European Influenza Vaccines Volume Market Share (%) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe



Global Influenza Vaccines Market Analysis (2012-2022) by Geographic Region – North America, Europe, Asia-Pacific, South & Central America and Middle East & Africa in Million Doses



KEY PLAYERS PROFILED

- Abbott Laboratories
- Astrazeneca PLC
- Biocryst Pharmaceuticals, Inc.
- CSL Limited
- Daiichi Sankyo Co., Ltd.
- Glaxosmithkline PLC
- Hualan Biological Engineering Inc.
- Instituto Butantan
- Microbix Biosystems Inc.
- Mitsubishi Tanabe Pharma Corporation
- Nanotherapeutics Inc.
- OPKO Health, Inc.
- Pfizer Inc
- Protein Sciences Corporation
- Roche Holding AG
- Sanofi SA
- Shanghai Institute of Biological Products Co., Ltd.
- Shionogi & Co., Ltd.
- Sinovac Biotech Ltd.
- Vivaldi Biosciences Inc.

.....more

TABLE OF CONTENTS

PART A: GLOBAL MARKET PERSPECTIVE 1

1. INTRODUCTION 1

1.1 Product Outline.....	2
1.1.1 What is Influenza?.....	2
1.1.2 Influenza Virus Types.....	2
1.1.3 Influenza Types.....	3
1.1.3.1 Seasonal Influenza.....	3
1.1.3.2 Pandemic Influenza.....	4
1.1.3.3 Zoonotic Influenza.....	4
1.1.4 Treatment of Influenza.....	4
1.1.4.1 Neuraminidase Inhibitors.....	4
1.1.4.2 M2 Inhibitors.....	4
1.1.5 Influenza Vaccine Production Technologies.....	5
1.1.5.1 Egg Based Vaccine Manufacturing Technology.....	5
1.1.5.2 Cell Culture Based Vaccine Manufacturing Technology.....	5
1.1.5.3 Recombinant Production Technology.....	5

2. MAJOR PRODUCTS IN PIPELINE 6

2.1 Influenza Vaccines in Pipeline.....	6
2.2 Influenza Therapeutics in Pipeline.....	8

3. KEY MARKET TRENDS 9

3.1 Development of Novel Anti-Influenza Drugs to be Guided by Research.....	9
3.2 Potential to Reduce Influenza-Associated Atrial Fibrillation Shown by Flu Vaccine.....	10
3.3 Designer Drugs for Combating Flu.....	10
3.4 Influenza Vaccines Based on Cell Culture Gaining Traction.....	12
Production of Influenza Vaccine Using Mammalian Cell Culture.....	12
Production of Influenza Vaccine Using Insect Cell Culture.....	13
3.5 Emerging Technologies for Influenza Vaccine Production.....	14
Virus-Like Particles Influenza Vaccine.....	14
Vectored Influenza Vaccine.....	15
Cell-Based Produced LAIV.....	16
3.6 Traditional Seasonal Flu Vaccines Confront Challenge from Plant-Based Vaccines!.....	17
3.7 HHS Makes Progress in Developing Innovative Drug for Treating Influenza.....	19

4. KEY GLOBAL PLAYERS 20

Abbott Laboratories (United States).....	20
Astrazeneca Plc (United Kingdom).....	21
Biocryst Pharmaceuticals, Inc. (United States).....	22
Csl Limited (Australia).....	23
Daiichi Sankyo Co., Ltd. (Japan).....	24
Glaxosmithkline Plc (United Kingdom).....	26
Hualan Biological Engineering Inc. (China).....	28
Instituto Butantan (Brazil).....	29
Mitsubishi Tanabe Pharma Corporation (Japan).....	30
Nanotherapeutics Inc. (United States).....	31
Protein Sciences Corporation (United States).....	32
Roche Holding AG (Switzerland).....	34
Sanofi SA (France).....	35
Shanghai Institute of Biological Products Co., Ltd. (China).....	37
Shionogi & Co., Ltd. (Japan).....	38
Sinovac Biotech Ltd. (China).....	39

5. KEY BUSINESS TRENDS 40

Roche in an Alliance with Shionogi for Anti-Flu Drug S-033188.....	40
Unveiling of Janssen Diagnostics' New Idylla™ Respiratory IFV-RSV Panel.....	40
Establishment of a New Corporate Office for Seqirus in the United Kingdom.....	40
Seqirus' FLUAD™ (Influenza Vaccine, Adjuvanted) Approved by US FDA.....	41

Mexican Regulatory Authorities Approved Flublok® Influenza Vaccine for Adults 18 and Older.....	41
Seqirus, World's No.2 Influenza Vaccine Provider.....	41
Sanofi Pasteur Presented New Synthetic Vaccine COBRA at the World Vaccine Congress in Spain.....	41
First CLIA-Waived, Real-Time PCR Test for Influenza A and B Detection in 20 Minutes.....	42
Nationwide Availability of Flublok® Influenza Vaccine.....	42
Sinovac Supplies Seasonal Influenza Vaccine for 2015 Vaccination Campaign in Beijing.....	42
Daiichi Sankyo Receives License to Develop and Commercialize FluMist® Quadrivalent in Japan.....	43
Janssen and the Scripps Research Institute to Develop a Universal Flu Vaccine.....	43
Novartis Influenza Vaccine Business Acquired by CSL.....	43
GSK and bioCSL Amp Flu Vaccine Dose Count Shipped to the US.....	44
Sanofi Pasteur's Flu Vaccines Meet the Immunization Needs of People of Multiple Age Groups.....	44
FDA Approved Protein Sciences' Flublok® Influenza Vaccine Formulated for the 2015-16 Flu Season.....	44
Outperformance of Flublok® Quadrivalent Compared to Conventional Influenza Vaccine.....	45
bioCSL Receives Exclusive Global Rights to Commercialize RAPIVAB®.....	45
Flublok® Receives FDA Regulatory Exclusivity for 12 Years under the Affordable Care Act.....	45
Cipla Joined Forces with Serum Institute for Exclusive Sale of Nasovac-S Flu Vaccine in India.....	46
Zydus Cadila to Introduce 10 Shots in the Indian Vaccines Market.....	46
Daiichi Sankyo Partner with Chemo-Sera-Therapeutic Research Institute to Sell Kaketsuken.....	46
US FDA Licensed Protein Sciences' New York Production Plant for Producing Flublok®.....	46
Japan Vaccine Applied for the Production and Sales Approval for The Vaccine in Japan.....	47
Release of Serum Institute's NasoVac S Vaccine to Protect People from H1N1 Virus and Influenza A and B.....	47
Alere™ i Influenza A & B test, the First-Ever CLIA Waived Molecular Test to Identify and Differentiate Influenza A and B Virus within 15 Minutes.....	47
CDC Receives Letter from Connecticut Representatives Urging the Purchase of Protein Sciences' Flublok Vaccine.....	48
Protein Sciences Form Pact to Assess Possible Sources for Flublok Influenza Vaccine from Japan.....	48
First Ever Approval from FDA for an Intravenous Flu Drug.....	48
Baxter's Patented Vero Cell Technology Platform Purchased by Nanotherapeutics.....	49
Protein Sciences' Flublok® Influenza Vaccine Effective Against H3N2 Viruses.....	49
Sanofi Pasteur Received Approval for the Supplemental Biologics License Application for Fluzone Intradermal Quadrivalent Vaccine from the US FDA.....	49
US FDA Approval for Protein Sciences' Flublok Influenza Vaccine for People Aged 18 and Older.....	50
Liomont Granted with an Exclusive License to Flublok® and Panblok® Influenza Vaccines for the Mexico Market and other Latin American Nations.....	50
Beijing CDC Chosen Sinovac to be a Supplier of Seasonal Influenza Vaccines to the Citizens of Beijing for 2014.....	50
Divestiture of Abbott's Ex-US Branded Generic Drug Business.....	51
Janssen and Vertex Inked an Exclusive License Deal to Develop, Produce and Commercialize VX-787.....	51
BARDA Exercised Option Period 2 of its Deal with Protein Sciences Corporation to Develop Flublok® and Panblok®.....	51
FDA Grants First Time Approval for Producing Cell-Based Flu Vaccines in the US.....	52
Astellas Pharma Submitted Application for Marketing Approval of Recombinant Influenza HA Vaccine in Japan.....	52
Japanese Ministry of Health, Labour and Welfare Chosen Kitasato Daiichi Sankyo Vaccine for the Initiative of Cell Culture Vaccine Production Facility Capacity Building.....	52
Clinical Trial Application with CFDA Submitted by Sinovac for its Patented H7N9 Vaccine.....	53

Acquisition of Key Supplier to BD Diagnostics' Point-of-Care Instrument Platform by BD.....	53
Daiichi Sankyo's Inavir® Inhibitor Approved for Use in the Japanese Market.....	53
AstraZeneca Receives EC Approval for Fluenz Tetra to Treat Seasonal Influenza in People aged 2-18 Years.....	53
US FDA Approved GSK's H5N1 Virus Monovalent Vaccine, Adjuvanted for Adults aged 18 and Older.....	54
New Phase III Clinical Studies of Recombinant Seasonal Influenza HA Vaccine ASP7374 Completed Successfully.....	54
PHARMAC Signed Influenza Vaccine Supply Deals with Abbott and GSK.....	54
US FDA's Proposed New Standards for Test Performance Improvement Accepted by BD.....	55
Fluzone High-Dose Vaccine Evidenced Superior Immune Responses than Standard Dose Fluzone Vaccine in the Prevention of Influenza in Older Adults.....	55
FDA Released the First lots of Sanofi Pasteur's Fluzone® for Shipment for the 2013-2014 Season.....	55
Special 510(k) Clearances Granted for Quidel's Updated Package Inserts for its Rapid Diagnostic Tests for Influenza.....	56
Medicago to Become the Joint Venture Company of Mitsubishi Tanabe Pharma and Philip Morris Investments.....	56
A New Drug Application to the Ministry of Health, Labour and Welfare in Japan for the Cell Culture-Based Pandemic Influenza Vaccine Filed by Kitasato Daiichi Sankyo Vaccine.....	56
FDA Approved Fluzone® Quadrivalent Vaccine for use in Patients of All Age Groups.....	56
New Vaccine for Protection from H7N9 Influenza Virus to be Developed by Protein Sciences.....	57
Production of Influenza Vaccine Restarted by bioCSL for the Australian Market.....	57
GSK's Quadrivalent Influenza Vaccine Receives Approval from PEI in Germany and MHRA in the UK.....	57
Protein Sciences' Flublok® Influenza Vaccine Receives Approval from the US FDA.....	58
FDA Extends its Approval for Tamiflu to Treat Influenza in Infants Aged Two Weeks and Older.....	58
First Intramuscular Vaccine to Cover Against Four Influenza Strains Received FDA Approval.....	58
Protein Sciences Signs Deal with Pfizer to Broaden Vaccine Production Operations.....	58
Daiichi Sankyo Filed an Application for a Partial Label Modification in Japan to Produce and Market Inavir® Dry Powder Inhaler.....	59
Outline of Phase II and Phase III Clinical Studies for Sanofi Pasteur's Investigational QIV Displayed at IDWeek™.....	59
US Government Selected CSL Biotherapies for Supplying Pre-Pandemic and Pandemic Vaccine Antigens.....	59
Beijing CDC Chosen Sinovac for Supplying Seasonal Influenza Vaccine to Beijing Citizens.....	59
Restructuring of Infectious Diseases and Vaccines R&D Operations by MedImmune.....	60
GSK Filed Regulatory Applications for Two of its Influenza Vaccines.....	60
Baxter's VEPACEL Pre-pandemic Influenza Vaccine Approved by European Commission.....	60
FluMist Quadrivalent, the first quadrivalent influenza vaccine approved by the FDA.....	60
Zydus Cadila, the First Indian Pharma Firm to Release Swine Flu Vaccine.....	60

6. GLOBAL MARKET OVERVIEW 61

Chart 1: Global Influenza Market Overview (2012-2022) by Segment – Vaccines and Therapeutics in USD Million.....	61
6.1 Global Influenza Vaccines Market Overview.....	62
Chart 2: Global Influenza Vaccines Market Overview (2012-2022) in Volume (Million Doses) and Value (USD Million).....	62
6.1.1 Global Influenza Vaccines Market Overview by Geographic Region.....	63
6.1.1.1 Market Analysis in Doses.....	63
Chart 3: Global Influenza Vaccines Market Analysis (2012-2022) by Geographic Region – North America, Europe, Asia-Pacific, South & Central America and Middle East & Africa in Million Doses.....	63

Chart 4: Glance at 2012, 2017 and 2022 Global Influenza Volume Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South & Central America and Middle East & Africa.....64	2.1 European Influenza Vaccines Market Overview by Geographic Region 82	BioDerm Ltd (Australia)..... 103
6.1.1.2 Market Analysis in USD 65	2.1.1 Market Analysis in Doses 82	Changchun Changsheng Life Sciences Limited (China) .. 103
Chart 5: Global Influenza Vaccines Market Analysis (2012-2022) by Geographic Region – North America, Europe, Asia-Pacific, South & Central America and Middle East & Africa in USD Million.....65	Chart 16: European Influenza Vaccines Market Analysis (2012-2022) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in Million Doses 82	China National Biotec Group (China) 103
Chart 6: Glance at 2012, 2017 and 2022 Global Influenza Value Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South & Central America and Middle East & Africa.....66	Chart 17: Glance at 2012, 2017 and 2022 European Influenza Vaccines Volume Market Share (%) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe..... 83	CSL Limited (Australia)..... 104
6.2 Global Influenza Therapeutics Market Overview67	2.1.2 Market Analysis in USD 84	Daichi Sankyo Co., Ltd. (Japan) 105
Chart 7: Global Influenza Therapeutics Market Analysis (2012-2022) by Geographic Region – United States, Europe, Japan and Rest of World in USD Million67	Chart 18: European Influenza Vaccines Market Analysis (2012-2022) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million 84	Dalian Aleph Biomedical Co., Ltd (China) 107
Chart 8: Glance at 2012, 2017 and 2022 Global Influenza Therapeutics Value Market Share (%) by Geographic Region – United States, Europe, Japan and Rest of World 68	Chart 19: Glance at 2012, 2017 and 2022 European Influenza Vaccines Value Market Share (%) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe..... 85	Gamma Vaccines Pty Limited (Australia) 107
PART B: REGIONAL MARKET PERSPECTIVE ... 69	2.2 Major Market Players 86	Green Cross Corporation (South Korea) 107
Chart 9: The Largest Independent Regions in Terms of Projected Growth (2016-2022) for Influenza Vaccines Market by Geographic Region – North America, Europe, Asia-Pacific, South & Central America and Middle East & Africa.....69	Astrazeneca PLC (United Kingdom) 86	Hualan Biological Engineering Inc. (China)..... 108
REGIONAL MARKET OVERVIEW..... 70	MedImmune, LLC (United States) 87	Kaketsuken (The Chemo-Sero-Therapeutic Research Institute) (Japan) 108
1. NORTH AMERICA 70	Federal State Scientific-Industrial Company MICROGEN (Russia) 88	Mitsubishi Tanabe Pharma Corporation (Japan)..... 109
Chart 10: North American Influenza Vaccines Market Overview (2012-2022) in Volume (Million Doses) and Value (USD Million) 70	Glaxosmithkline PLC (United Kingdom)..... 89	Serum Institute of India Pvt. Ltd (India) 110
1.1 North American Influenza Vaccines Market Overview by Geographic Region 71	Japan Vaccine Co., Ltd. (Japan) 91	Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (China) ... 110
1.1.1 Market Analysis in Doses 71	NTPharma LLC (Russia)..... 92	Shanghai Institute of Biological Products Co., Ltd. (China) ... 111
Chart 11: North American Influenza Vaccines Market Analysis (2012-2022) by Geographic Region – United States, Canada and Mexico in Million Doses 71	OMNINVEST Vaccine Manufacturing, Researching and Trading Ltd (Hungary) 92	Shionogi & Co., Ltd. (Japan) 112
Chart 12: Glance at 2012, 2017 and 2022 North American Influenza Vaccines Volume Market Share (%) by Geographic Region – United States, Canada and Mexico 72	Roche Holding AG (Switzerland) 93	Sinovac Biotech Ltd. (China) 113
1.1.2 Market Analysis in USD 73	Sanofi SA (France) 94	SK Chemicals (South Korea)..... 114
Chart 13: North American Influenza Vaccines Market Analysis (2012-2022) by Geographic Region – United States, Canada and Mexico in USD Million 73	Sanofi Pasteur MSD (France)..... 96	UMN Pharma Inc. (Japan) 115
Chart 14: Glance at 2012, 2017 and 2022 North American Influenza Vaccines Value Market Share (%) by Geographic Region – United States, Canada and Mexico 74	3. ASIA-PACIFIC..... 97	4. SOUTH & CENTRAL AMERICA 116
1.2 Major Market Players 75	Chart 20: Asia-Pacific Influenza Vaccines Market Overview (2012-2022) in Volume (Million Doses) and Value (USD Million) 97	Chart 25: South & Central American Influenza Vaccines Market Overview (2012-2022) in Volume (Million Doses) and Value (USD Million)..... 116
Abbott Laboratories (United States)75	3.1 Asia-Pacific Influenza Vaccines Market Overview by Geographic Region 98	4.1 South & Central American Influenza Vaccines Market Overview by Geographic Region 117
BioCryst Pharmaceuticals, Inc. (United States)76	3.1.1 Market Analysis in Doses 98	4.1.1 Market Analysis in Doses 117
Microbix Biosystems Inc. (Canada)76	Chart 21: Asia-Pacific Influenza Vaccines Market Analysis (2012-2022) by Geographic Region – China, India, Japan, South Korea, Australia and Rest of Asia-Pacific in Million Doses 98	Chart 26: South & Central American Influenza Vaccines Market Analysis (2012-2022) by Geographic Region – Argentina, Brazil, Chile, Columbia, Venezuela and Rest of South America in Million Doses 117
Nanotherapeutics Inc. (United States).....77	Chart 22: Glance at 2012, 2017 and 2022 Asia-Pacific Influenza Vaccines Volume Market Share (%) by Geographic Region – China, India, Japan, South Korea, Australia and Rest of Asia-Pacific 99	Chart 27: Glance at 2012, 2017 and 2022 South & Central American Influenza Vaccines Value Market Share (%) by Geographic Region – Argentina, Brazil, Chile, Columbia, Venezuela and Rest of South America 118
OPKO Health, Inc. (United States)78	3.1.2 Market Analysis in USD 100	Chart 28: South & Central American Influenza Vaccines Market Analysis (2012-2022) by Geographic Region – Argentina, Brazil, Chile, Columbia, Venezuela and Rest of South America 119
Pfizer Inc (United States)78	Chart 23: Asia-Pacific Influenza Vaccines Market Analysis (2012-2022) by Geographic Region – China, India, Japan, South Korea, Australia and Rest of Asia-Pacific in USD Million 100	Chart 29: Glance at 2012, 2017 and 2022 South & Central American Influenza Vaccines Value Market Share (%) by Geographic Region – Argentina, Brazil, Chile, Columbia, Venezuela and Rest of South America 120
Protein Sciences Corporation (United States).....79	Chart 24: Glance at 2012, 2017 and 2022 Asia-Pacific Influenza Vaccines Value Market Share (%) by Geographic Region – China, India, Japan, South Korea, Australia and Rest of Asia-Pacific..... 101	4.2 Instituto Butantan (Brazil) – Major Market Player. 121
Vivaldi Biosciences Inc. (United States)80	3.2 Major Market Players 102	5. MIDDLE EAST & AFRICA 122
2. EUROPE 81	Beijing Tiantan Biological Products Co., Ltd (China) 102	Chart 30: Middle East & Africa Influenza Vaccines Market Overview (2012-2022) in Volume (Million Doses) and Value (USD Million) 122
Chart 15: European Influenza Vaccines Market Overview (2012-2022) in Volume (Million Doses) and Value (USD Million)81	BIKEN (The Research Foundation for Microbial Diseases of Osaka University) (Japan)..... 102	PART C: GUIDE TO THE INDUSTRY..... 123
		1. NORTH AMERICA 123
		2. EUROPE 124
		3. ASIA-PACIFIC 125
		4. REST OF WORLD 126
		PART D: ANNEXURE 127
		1. RESEARCH METHODOLOGY 127
		2. FEEDBACK 129

About Industry Experts

Industry Experts values the most updated and accurate market research and industry analysis to provide unique market research reports for a broad range of industry verticals including Automotive, Transportation, Healthcare, Pharmaceuticals, Food & Beverages, Chemicals, Plastics, Materials, Consumer Goods, Retail, Biotechnology, Construction, Manufacturing and Other industries. Our research reports help our clients to identify and resolve topical issues by providing a complete picture of the market in their respective industry sectors. The Company's rich collection of market research reports enable the companies to explore market drivers; forecast the future market; and to formulate the right strategies at the right time.

Industry Experts' leading edge publications makes the life easy for corporate strategists, investors, analysts and researchers, start ups, consultants, financial and banking executives, academicians and many more. The company also provides customized research reports to cater the needs of the industry.

[More about Industry Experts](#)

Industry Experts
Redefines Business Acumen

INDUSTRY EXPERTS

1-7-19/C, Street No. 8, Habsiguda
Hyderabad – 500007, India
Phone: +91-40-4018-1314
Fax: +91-40-4027-2381
info@industry-experts.com
industry-experts.com